1.Wang DX, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol. 2019 Apr 24;12(1):42. doi: 10.1186/s13045-019-0730-9. PMID: 31014381; PMCID: PMC6480748.(影响因子11.059;1区;Journal of Hematology Oncology;共一第一)
2.Wang DX, Yang X, Long J, Lin J, Mao J, Xie F, Wang Y, Wang Y, Xun Z, Bai Y, Yang X, Guan M, Pan J, Seery S, Sang X, Zhao H. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. Front Oncol. 2021 Apr 12;11:646979. doi: 10.3389/fonc.2021.646979. PMID: 33912461; PMCID: PMC8071846.(影响因子4.84;2区;Frontiers in Oncology;共一第一)
3.Wang DX, Yang X, Lin J, Bai Y, Long J, Yang X, Seery S, Zhao H. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therap Adv Gastroenterol. 2020 Jun 23;13:1756284820932483. doi: 10.1177/1756284820932483. PMID: 32636928; PMCID: PMC7313339.影响因子3.52;2区;Therapeutic Advance in Gastroenterology;(共一第一)
4.Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol. 2020 Aug 14;26(30):4465-4478. doi: 10.3748/wjg.v26.i30.4465. PMID: 32874058; PMCID: PMC7438196.(影响因子3.665;2区;World Journal of Gastroenterology;独立第一)
5.Wang DX, Seery S, Zhao H. Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer. JAMA Oncol. 2020 Dec 1;6(12):1981. doi: 10.1001/jamaoncol.2020.4815. PMID: 33090192.(影响因子24.799;1区;JAMA Oncology;独立第一)
6.Yang X,Wang DX, Lin J, Yang X, Zhao H. Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Lancet Oncol. 2020 Sep;21(9):e412. doi: 10.1016/S1470-2045(20)30430-7. PMID: 32888462.(影响因子33.752;1区;Lancet Oncolgy;共一第二)
7.Yang X, Hu Y, Yang K,Wang DX, Lin J, Long J, Xie F, Mao J, Bian J, Guan M, Pan J, Huo L, Hu K, Yang X, Mao Y, Sang X, Zhang J, Wang X, Zhang H, Zhao H. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer. 2021 May;9(5):e001942. doi: 10.1136/jitc-2020-001942. PMID: 33972389.(影响因子9.9;1区;Journal for ImmunoTherapy of Cancer;共一第四)
8.Jianzhen Lin, Songhui Zhao, Dongxu Wang, Yang Song, Yue Che, Xu Yang, Jinzhu Mao, Fucun Xie, Junyu Long, Yi Bai, Xiaobo Yang, Lei Zhang, Jin Bian, Xin Lu, Xinting Sang, Jie Pan, Kai Wang, Haitao Zhao “Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.” Frontiers in immunology vol. 12 673248. 15 Jun. 2021, doi:10.3389/fimmu.2021.673248(影响因子7.3;2区;Frontiers in immunology;共一第二)
9.Junyu Long # 1, Dongxu Wang # 1, Xu Yang # 1, Anqiang Wang 2, Yu Lin 3, Mingjun Zheng 4, Haohai Zhang 5, Xinting Sang 1, Hanping Wang 6, Ke Hu 7, Haitao Zhao “Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.” BMC medicine vol. 19,1 154. 21 Jul. 2021, doi:10.1186/s12916-021-02031-3(影响因子9.3;1区;BMC Medicine volume 19, Article number: 154 (2021);共一第二)
10.Mao J,Wang Dongxu, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2021 Dec;9(12):e003334. doi: 10.1136/jitc-2021-003334. PMID: 34873013; PMCID: PMC8650503.(影响因子10.9;1区;Journal for ImmunoTherapy of Cancer;共一第二)
11.Junyu Long # 1, Dongxu Wang # 2, Anqiang Wang # 3, Peipei Chen # 4, Yu Lin, Jin Bian, Xu Yang, Mingjun Zheng, Haohai Zhang, Yongchang Zheng, Xinting Sang, Haitao Zhao “A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.” Genome medicine vol. 14,1 20. 24 Feb. 2022, doi:10.1186/s13073-022-01024-y(影响因子12.3;1区;Genome Medicine,共一第二)
12.Yun-Long Ma, Ya-Fei Yang, Han-Chao Wang, Chun-Cheng Yang, Lun-Jie Yan, Zi-Niu Ding, Bao-Wen Tian, Hui Liu, Jun-Shuai Xue, Cheng-Long Han, Si-Yu Tan, Jian-Guo Hong, Yu-Chuan Yan, Xin-Cheng Mao,Dong-Xu Wang, Tao Li. “A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response.”Frontiers in pharmacologyvol. 14 1101749. 24 Feb. 2023, doi:10.3389/fphar.2023.1101749(影响因子5.6;2区;Frontiers in Pharmacology,共同通讯)
13.Jun-Yu Long, Rui-Zhe Li,Dong-Xu Wang, Hui Liu, Jincheng Tian, Zi-Niu Ding, Lun-Jie Yan, Zhao-Ru Dong, Jian-Guo Hong, Bao-Wen Tian, Cheng-Long Han, Hai-Tao Zhao, Tao Li. “Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.” International immunopharmacology vol. 126 (2024): 111281. doi:10.1016/j.intimp.2023.111281(影响因子5.6;2区;International Immunopharmacology, Volume 126, 5 January 2024, 111281,共一第三)
14.Hui Liu, Han Li,Dong-Xu Wang, Tao Li. “Letter to the Editor: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.”Hepatology (Baltimore, Md.), 10.1097/HEP.0000000000000718. 13 Dec. 2023, doi:10.1097/HEP.0000000000000718(影响因子14.0;1区;Hepatology,共同通讯)
15.Wang, Dong-Xu et al.“Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments.” Molecular cancer vol. 23,1 15. 15 Jan. 2024, doi:10.1186/s12943-023-01930-8
16.Wang, Dong-Xu et al.“Neoadjuvant immunotherapy based on PD-1/L1 Inhibitors for gastrointestinal tumor: a review of rationale and clinical advances.” International journal of surgery (London, England), 10.1097/JS9.0000000000001357. 21 Mar. 2024, doi:10.1097/JS9.0000000000001357